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It’s hard to keep all things angiogenic in one JAR!
Journal of Angiogenesis Research has become “Vascular
Cell“.
“All things angiogenic” could mean many things to the
many different types of researchers in the field. This
diversity of thought is clearly reflected by the articles
presented since the launch of the Journal of Angiogenesis
Research (JAR) just over a year ago. Clinicians, scientists
and educators have used the open access journal JAR,t o
present a variety of studies and concepts related to
angiogenesis. Over the last year, JAR has presented
reviews on Notch ligands found in vessels [1], Wnts in
the brain vasculature [2], endothelial cell function of
relevance to the cardiologist [3], and imaging paradigms
to study and diagnose diseases of the vasculature [4].
Research reports on contraceptive-induced angiogenesis
[5], on novel angiogenic regulators [6], and on capillary
size and vascular permeability [7] represented some of
the most highly accessed articles published in JAR.T h e
field is large, diverse, exciting, and fast-paced. With
notable ease, the field bridges the disciplines of medical
diagnosis and treatment with that of fundamental
scientific discovery. The field is relevant; serving as the
basis of development of new drugs that are being used
to treat cancer patients; those suffering from vision loss,
diabetics, and those with other illnesses.
As a result of this diversity of thoughts, of research
topics, and of researchers, we came to realize that all
things angiogenic/vascular could not be kept in one
single JAR! The publication platform, developed as a
venue for angiogenic researchers, was found to be rele-
vant and of interest to researchers studying the many
facets of human vasculature, not limited to those who
study the construction of new vessels. Journal of Angio-
genesis Research has grown into new areas and new
frontiers of research. Our stated aim was “to publish
articles from all areas of the ‘broad spectrum’ of vascular
research and from the bench to the bed-side”
(September 2009). To best achieve this aim, we here
present a new name for the journal, Vascular Cell.
Vascular Cell will focus on the vasculature in health
and disease. Appreciated by the earliest anatomists and
physicians, the vasculature is now being redefined. The
vasculature is a dynamic structure that is built and
rebuilt. Although early researchers focused on endothe-
lial cells and started with a limited knowledge of “peri-
vascular” cells, the vasculature is built from a wide
variety of cell types and influenced by an even wider
array of cells. The last decade of vascular research has
been exemplified by a wider appreciation of what the
vasculature is and of what it is made up of. We learned
that endothelial cells come from several sources, even
pathologically mutated cells! We learned that the human
vasculature can be influenced by immune cells, nervous
system cells, endocrine cells; in short, cells from all
types of tissues. Contemporary research seeks to under-
stand how these diverse cell types integrate signals to
generate a functional vasculature. Diseases of the vascu-
lature will be better understood, and hopefully better
treated, by studying all cells of the vasculature. In the
spirit of this broader definition of the vasculature, the
new name represents an essentially broader focus for
the journal. We hope that Vascular Cell serves as the
venue to present timely research and thought on the
multi-faceted vasculature in the 21
st century.
Vascular biology including angiogenesis research is
one of the fastest expanding fields in biomedical
research. Almost all developmental processes are
coupled to vascular growth, remodeling and functions.
Structural or functional defects of the vascular network
are tightly linked to the onset, development and pro-
gression of various human diseases including those most
common and lethal disorders such as cancer, cardiovas-
cular disease, obesity, metabolic disorders and chronic
inflammation. While major scientific journals such as
Cell and Nature series cover other rapidly developing
fields, including immunology, neuroscience, stem cell,
cancer and infection, vascular biology has not been
highlighted as a major field standing on its own. Our
goal is to establish Vascular Cell as one of the top
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articles in this field. Importantly, we hope that this
journal will further boost research interests from other
fields in connection to vascular biology. We also empha-
size the translational research bridging basic research to
clinical implications and vice versa. As several FDA-
approved anti-angiogenic drugs are in clinical use for
the treatment of malignant and non-malignant diseases,
vascular translational research will add unprecedented
values to clinical practice of these targeted drugs. We
are aiming to set up the highest standard for publishing
primary research, translational research, clinical, metho-
dological, case reports and review articles.
Specific examples of this overlapping/novel technology
include recent developments in tissue engineering,
where human fibroblasts extracted from skin biopsies
were formed into a cohesive sheet and then used as a
matrix to engineer new blood vessels using Teflon-
coated stainless steel support tubes and attachment of
an internal membrane and peripheral adventitial coating
using patient-only cells. These have been shown to be
antithrombogenic and stable for extended periods of
time and could provide a valuable alternative to the use
of synthetic or xenogeneic vessels for transplant in
patients with advanced cardiovascular disease [8]. Nano-
technology will have an increasing role in development
of scaffolding, targeting of molecules and imaging plat-
forms over the next few years. Optimizing the process
of vascularization/angiogenesis is important in the treat-
ment of ischaemic disease, and Sinha Roy et al [9]
demonstrated this recently by encapsulating NK1 (a
splice variant of hepatocyte growth factor) in biodegrad-
able nanoparticles composed of D, L-lactic acid-co-
glycolic acid copolymer, and demonstrated both tem-
poral release and enhanced vascularization in a matri-
gel-implanted zebrafish model of vasculogenesis.
In other vascular diseases, including neurodegenerative
diseases such as Alzheimer’s, understanding the
mechanisms that cause vascular abnormalities and
impair cerebral blood flow could provide some of the
answers to the importance of ischaemia (possibly
initiated following ischaemic or lacunar stroke) in for-
mation of vascular amyloidosis and dense-core plaques
[10]. Newly developed and currently developing vascular
imaging techniques may help us to identify earlier,
patients at risk of progressing to pre-senile dementia,
and also could be useful in detecting vascular-associated
lesional changes after stroke, and in primary (e.g. glio-
blastoma) or metastasized brain tumours. In this
respect, Kienast et al [11] used multiphoton laser scan-
ning microscopy to image single steps of metastasis for-
mation in a mouse brain in real-time. Translated to
humans, understanding the individual fate of tumour
cells, their movement through microvessels and
perivascular growth could help us modify existing thera-
peutic strategies. These are only a few examples of the
r a n g eo ft o p i c sa p p r o p r i a t et ob ei n c l u d e di nVascular
Cell. A review of the processes of angiogenesis and vas-
cularization in all the major diseases is presented in the
recent book published recently by Springer entitled
("Therapeutic angiogenesis”, Molecular Mechanisms and
Targeted Clinical Approaches for the Treatment of
Angiogenic Disease [12].
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